Alnylam Pharmaceuticals is an independent biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. These medicines work by silencing genes that contribute to diseases, providing a method of treatment. Alnylam has developed several RNAi therapeutics that have received regulatory approval, targeting both rare and prevalent diseases. The company operates globally, leveraging its expertise in genetic medicine to address various health conditions.
- Website
- www.alnylam.com
- Issuer profile
- All listings